Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease.
Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease.
复制标题
优化来自普乐沙福动员的镰状细胞病患者的造血干细胞和祖细胞单采采集。
DOI：
10.1111/bjh.18311
复制
发表时间：
2022
影响因子：
6.5
通讯作者：
Zheng
中科院分区：
文献类型：
--
作者：
Sharma,Akshay;Leonard,Alexis;West,Kamille;Gossett,JeffreyM;Uchida,Naoya;Panch,Sandhya;Stroncek,David;Poston,Leigh;Akel,Salem;Hankins,JaneS;Fitzhugh,Courtney;Hsieh,MatthewM;Kang,Guolian;Tisdale,JohnF;Weiss,MitchellJ;Zheng
我们调整了镰状细胞病（SCD）患者的造血干细胞和祖细胞（HSPC）单采收集，采用中等或低收集偏好（CP）靶向深褐色被收集，并增加抗凝剂柠檬酸盐-葡萄糖溶液A的剂量。在43例动员了plerixafor的成年SCD患者的HSPC收集中，我们使用中CP和低CP分别将收集效率提高到35.79%和82.23%。深啡色被收集增加了HSPC产品的红细胞污染，中CP和低CP的产品红细胞压积分别为4.7%和6.4%。这些调整具有良好的耐受性，并允许从SCD患者中有效收集HSPC。
We adjusted haematopoietic stem and progenitor cell (HSPC) apheresis collection from patients with sickle cell disease (SCD) by targeting deep buffy coat collection using medium or low collection preference (CP), and by increasing anticoagulant–citrate–dextrose–solution A dosage. In 43 HSPC collections from plerixafor‐mobilized adult patients with SCD, we increased the collection efficiency to 35.79% using medium CP and 82.23% using low CP. Deep buffy coat collection increased red blood cell contamination of the HSPC product, the product haematocrit was 4.7% with medium CP and 6.4% with low CP. These adjustments were well‐tolerated and allowed efficient HSPC collection from SCD patients.